title: Nasal allergies in the Latin American population: results from the Allergies in Latin America survey.
abstract: Allergies in Latin America is the first cross-national survey that describes the symptoms, impact, and treatment of nasal allergies (NAs) in individuals >or=4 years old in Latin America (LA). In total, 22,012 households across the Latin American countries of Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Venezuela were screened for children, adolescents, and adults with a diagnosis of NA and either symptoms or treatment in the past 12 months. A total of 1088 adults and 457 children and adolescents were included and the sample was probability based to ensure valid statistical inference to the population. Approximately 7% of the LA population was diagnosed with NAs with two of three respondents stating that their allergies were seasonal or intermittent in nature. A general practice physician or otolaryngologist diagnosed the majority of individuals surveyed. Nasal congestion was the most common and bothersome symptom of NAs. Sufferers indicated that their symptoms affected productivity and sleep and had a negative impact on quality of life. Two-thirds of patients reported taking some type of medication for their NAs, with a roughly equal percentage of patients reporting taking over-the-counter versus prescription medications. Changing medications was most commonly done in those reporting inadequate efficacy. The most common reasons cited for dissatisfaction with current medications were related to inadequate effectiveness, effectiveness wearing off with chronic use, failure to provide 24-hour relief, and bothersome side effects (e.g., unpleasant taste and retrograde drainage into the esophagus). Findings from this cross-national survey on NAs have confirmed a high prevalence of physician-diagnosed NAs and a considerable negative impact on daily quality of life and work productivity as well as substantial disease management challenges in LA. Through identification of disease impact on the LA population and further defining treatment gaps, clinicians in LA may better understand and treat NAs, thus leading to improvements in overall patient satisfaction and quality of life.
authors.affiliation: Respiratory Medicine Unit, Children's Hospital Orlando Alassia, Santa Fe, Argentina. hugoneffen@arnet.com.ar
authors.forename: Hugo
authors.initials: H
authors.lastname: Neffen
authors.forename: Joao F
authors.initials: JF
authors.lastname: Mello
authors.forename: Dirceu
authors.initials: D
authors.lastname: Sole
authors.forename: Charles K
authors.initials: CK
authors.lastname: Naspitz
authors.forename: Alberto Eduardo
authors.initials: AE
authors.lastname: Dodero
authors.forename: Héctor León
authors.initials: HL
authors.lastname: Garza
authors.forename: Edgard Novelo
authors.initials: EN
authors.lastname: Guerra
authors.forename: Carlos
authors.initials: C
authors.lastname: Baez-Loyola
authors.forename: John M
authors.initials: JM
authors.lastname: Boyle
authors.forename: Mark A
authors.initials: MA
authors.lastname: Wingertzahn
mesh_terms: D000293:Adolescent; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D003625:Data Collection; D006801:Humans; D007843:Latin America / Q000453:epidemiology; D017060:Patient Satisfaction; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*
chemical_list: D018926:Anti-Allergic Agents